Corcept Therapeutics Incorporated - Common Stock (CORT)
91.57
+0.00 (0.00%)
NASDAQ· Last Trade: Jul 21st, 7:45 AM EDT
Detailed Quote
Previous Close
91.57
Open
-
Bid
91.00
Ask
94.95
Day's Range
N/A - N/A
52 Week Range
28.66 - 95.11
Volume
216
Market Cap
10.62B
PE Ratio (TTM)
111.67
EPS (TTM)
0.8
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,112,850
Chart
About Corcept Therapeutics Incorporated - Common Stock (CORT)
Corcept Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative treatments for patients with severe metabolic and psychiatric disorders. The company primarily specializes in the modulation of glucocorticoid signaling, a pathway that plays a key role in various diseases, particularly those characterized by chronic stress and inflammation. Corcept's lead product is designed to help patients suffering from conditions such as Cushing's syndrome, and the company is also engaged in research aimed at expanding its therapeutic applications to broader health issues. Through its dedication to advancing scientific understanding and developing effective therapies, Corcept aims to improve the quality of life for patients battling these challenging health conditions. Read More
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they strugg...
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expecta...
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced the presentation of new data from its CATALYST and MOMENTUM trials at the American Diabetes Association’s 86th Scientific Sessions. The presentations underscore the critical role of hypercortisolism in difficult-to-control type 2 diabetes and resistant hypertension, and the potential of cortisol modulation treatment.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (American Society of Clinical Oncology) Annual Meeting.
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing’s syndrome.
Corcept’s stock price has taken a beating over the past six months, shedding 35% of its value and falling to $50.98 per share. This was partly driven by its ...
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ...
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 4.9% year on year to $164.9 million...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2026.
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Thursday after market hours. Here’s what to look for. Corcept m...
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on April 30, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
